Explore our globally verified chemical compounds, small molecule active pharmaceutical ingredients (APIs), and specialty peptides exported direct from accredited manufacturing facilities.
Sunitinib Malate (CAS No: 341015-70-7, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide L-malate) represents a cornerstone multi-targeted receptor tyrosine kinase (RTK) inhibitor. By selectively blocking vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-α, PDGFR-β), stem cell factor receptor (c-KIT), FLT3, and RET, Sunitinib has revolutionized targeted oncology regimens worldwide.
As primary drug patents for innovator formulations (Sutent®) expire across international jurisdictions, the global demand for high-grade generic Sunitinib Malate API has surged. Chinese chemical manufacturers and export hubs have positioned themselves as pivotal anchors in the global pharmaceutical supply chain. Leveraging extensive chemical synthesis infrastructure, advanced regulatory filing capabilities, and robust backwards-integrated raw material networks, China sunitinib exporters supply over 60% of the worldwide generic market volume.
To meet strict international pharmacopeial standards (USP, Ph. Eur.), top China Sunitinib exporters enforce stringent controls on critical quality attributes (CQAs). Specifically, controlling the (Z)-isomer ratio (≥99.0%), monitoring related substances (Impurity A through G to < 0.10%), limiting residual organic solvents (methanol, ethanol, DMF), and restricting elemental impurities per ICH Q3D guidelines are mandatory metrics for cGMP batches.
The industrial production of Sunitinib Malate demands a multi-step organic synthesis framework optimized for high atom economy, structural fidelity, and polymorph stability. Premier Chinese export facilities utilize standardized synthetic pathways that eliminate hazardous intermediates while maximizing stoichiometric efficiency.
Reaction of 5-fluoroisatin with 2,4-dimethyl-1H-pyrrole-3-carboxylic acid ester under basic conditions yields the core indolin-2-one pyrrole backbone. Temperature control (65°C - 75°C) is critical to prevent dimerization and side-chain thermal degradation.
Amidation using N,N-diethylethylenediamine converts the ester precursor to Sunitinib base. Precision monitoring ensures incomplete conversion residuals stay well below 0.05% before salt formation.
Equimolar reaction with L-malic acid in specified solvent mixtures (e.g., methanol/isopropanol) under controlled cooling profiles yields polymorphic Form I Sunitinib Malate, guaranteeing target bioequivalence and dissolution kinetics.
| Analytical Parameter | Pharmacopeial Requirement | China Exporters standard Quality (cGMP) | Testing Method |
|---|---|---|---|
| Chemical Purity (Assay) | 98.0% – 102.0% (Dried basis) | ≥ 99.5% | HPLC-UV (254 nm / 430 nm) |
| Isomeric Purity (Z-Isomer) | ≥ 98.5% | ≥ 99.8% | Chiral HPLC |
| Individual Impurity | ≤ 0.15% | ≤ 0.05% | LC-MS / HPLC |
| Genotoxic Impurities (GTIs) | TTC threshold (< 1.5 µg/day) | Undetectable (< 1 ppm) | GC-MS/MS |
| Polymorphic Form | Form I consistency | Pure Form I (100% Crystalline) | XRPD & DSC analysis |
| Particle Size (Micronized) | Customer Specified | D90 < 10 µm available | Laser Diffraction (Malvern) |
Navigating the complex global regulatory landscape requires a supply chain partner capable of offering continuous stability, rapid batch scaling, and full vertical integration. Leading China Sunitinib exporters operate within unified chemical industrial clusters (predominantly in Jiangsu, Zhejiang, and Shandong provinces), yielding unprecedented strategic efficiencies.
Chinese exporters synthesize key starting materials (KSMs)—including 5-fluoroisatin and diethylaminoethylamine—in-house. This protects global buyers from upstream supply bottlenecks, price volatility, and geopolitical disruptions.
Modern manufacturing footprints feature multi-ton glass-lined reactor suites, automated cleanroom isolation units (Class 100,000 / ISO 8), continuous flow crystallization setups, and dedicated micronization suites to support scale-up from batch validation to commercial multi-ton distribution.
Advanced solvent recovery loops, automated hazardous waste scrubbers, and catalytic reaction optimizations decrease carbon intensity while ensuring compliance with stringent national environmental regulations, guaranteeing zero supply interruptions.
Sunitinib Malate API supplied by Chinese manufacturing partners serves diverse dosage form developments and localized therapeutic deployment strategies across international markets:
The primary commercial application remains oral capsule formulations (12.5 mg, 25 mg, 37.5 mg, and 50 mg strengths). Sunitinib API produced with tailored bulk density and tight particle size distribution (PSD) guarantees powder flowability and uniform fill-weights during high-speed encapsulation.
With ongoing clinical research exploring synergy between TKIs and novel peptide therapeutics or checkpoint inhibitors, high-purity Sunitinib serves oncology research institutions and biotech developers evaluating combination therapies against resistant metastatic Renal Cell Carcinoma (mRCC) and Gastrointestinal Stromal Tumors (GIST).
China exporters provide comprehensive drug master files (DMF) alongside Finished Dosage Form (FDF) licensing out services, allowing pharmaceutical companies in Latin America, Southeast Asia, Africa, and Eastern Europe to localize secondary manufacturing with turnkey technology support.
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specially, representatives are established in Mexico and South Africa. Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
An overall factory construction area of 250,000 square meters under international standard to offer flexible, scalable and cost-effective solutions.
Gentolex offers an extensive range of APIs and intermediates for development study and commercial application with cGMP standard from long-term collaborations. Documents and Certificates are supported to customers worldwide.
For those clients who prefer to avoid the complexity of dealing with multiple points of contact, we provide extra customized procurement services with the most superior and comprehensive supply chain sources.
Quality Certifications & Operational Compliance Network
Stay informed with technical research papers, active pharmaceutical ingredient analyses, and peptide chemistry breakthroughs published by our QA team.
Introduction to Selank Acetate API Selank Acetate API is a synthetic heptapeptide active pharmaceutical ingredient composed of the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). Originally developed through neuropharmacological research, Selank is a synthetic derivative of the endogenous regulatory peptide tuftsin.
Read Full Technical Report →
Trusted Thymosin Beta-4 API Manufacturer and Global Peptide Supplier As a professional Thymosin Beta-4 API manufacturer and supplier, we provide high-quality Thymosin Beta-4 peptide API solutions for biotechnology companies, pharmaceutical research organizations, and laboratory clients worldwide.
Read Full Technical Report →
Introduction BPC-157 API is a synthetic pentadecapeptide that has gained increasing attention in peptide research due to its potential biological activities related to tissue repair, gastrointestinal protection, angiogenesis, and inflammatory regulation.
Read Full Technical Report →
With the continuous development of neuroscience, peptide technology, and life science research, neuroactive peptides have become an important area of scientific investigation. Semax, a synthetic peptide derived from an ACTH fragment, has attracted global interest.
Read Full Technical Report →
SS-31 API, also known as Elamipretide, MTP-131, Bendavia, and SS31, is a synthetic mitochondria-targeting tetrapeptide designed to bind cardiolipin in the inner mitochondrial membrane, stabilizing cellular bioenergetics.
Read Full Technical Report →Achieving frictionless cross-border distribution of Sunitinib Malate requires absolute fidelity to global pharmaceutical regulatory standards. Professional Chinese export managers provide complete regulatory dossier packages tailored to regional health authority demands:
Comprehensive Drug Master Files (US FDA DMF format, EU CTD Format Module 3) are provided. Technical packages include complete manufacturing route disclosures, process validation data, impurity profiling, and stability testing reports.
Every production batch undergoes long-term and accelerated stability testing in compliance with ICH Q1A(R2) standards (25°C/60% RH, 30°C/65% RH, and 40°C/75% RH). Data packages demonstrate 36-month shelf-life stability in sealed protective containers.
Facilities welcome third-party quality audits by global generic formulation partners. Virtual video audits, analytical method validation transfers, and complete Certificate of Analysis (CoA) verifications are integrated standard practices.
Browse our additional catalog of precision-synthesized organic plasticizers, high-purity peptide raw materials, and pharmaceutical APIs.
In-depth technical answers addressing common procurement inquiries, analytical standards, packaging, and regulatory documentation for global buyers.
